Roche goes hostile, cuts Genentech bid to $42 billion

ZURICH (Reuters) – Roche cut the price of its bid for outstanding shares in Genentech, going hostile and dashing investor hopes of a sweetened offer for the 44 percent of the U.S. biotech group its does not already own.

Leave a Reply